Replimune Group Business Summary

Replimune Group, Inc. (REPL) is a clinical-stage biotechnology company specializing in the development of oncolytic immunotherapies designed to activate a systemic anti-tumor immune response. The company operates as a pre-revenue entity, with its business model centered on the clinical advancement and eventual commercialization of its proprietary RPx platform, which utilizes engineered strains of herpes simplex virus 1 (HSV-1) to target solid tumors. Its primary business segments are categorized by its pipeline candidates: RP1 (vusolimogene oderparepvec), currently under FDA review for anti-PD-1 failed melanoma with a PDUFA date of April 10, 2026; RP2, focused on uveal melanoma and liver cancers; and RP3, targeting advanced solid tumors. Replimune competes in the immuno-oncology space against firms such as Adaptive Biotechnologies, Telix Pharmaceuticals, and Dyne Therapeutics, positioning itself as a niche leader in the oncolytic virus sector as it transitions from R&D to a commercial-stage organization. The company was founded in 2015 by a veteran team from BioVex (acquired by Amgen), including Robert Coffin, Ph.D., Philip Astley-Sparke, and Colin Love, Ph.D. The current leadership is headed by CEO Sushil Patel, Ph.D., who took the helm in April 2024 following senior roles at Genentech, and Founder/President Robert Coffin, who serves as the primary technical lead (Chief Research & Development Officer) and was the inventor of the first FDA-approved oncolytic therapy, Imlygic. Other key executives include CFO Emily Hill, CMO Konstantinos Xynos, and Executive Chairman Philip Astley-Sparke. The company is backed by notable institutional investors including Atlas Venture, Forbion, and Redmile Group, and maintains a strategic debt facility with Hercules Capital to fund operations through early 2027.